At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PTIX Protagenic Therapeutics, Inc.
Market Closed 11-06 16:00:01 EST Delay
盘后0.5400
+0.00000.00%
16:00 EST
Protagenic Therapeutics Secures $250,000 Loan from Patness
Reuters  ·  03:16
Protagenic Therapeutics Secures $250,000 Loan from Patness
Protagenic Therapeutics Executive Chair Garo H. Armen Acquires 20,000 Common Shares for $13,000
Reuters  ·  08-25
Protagenic Therapeutics Executive Chair Garo H. Armen Acquires 20,000 Common Shares for $13,000
Protagenic Therapeutics Executive Chair Garo H. Armen Acquires 2,700 Common Shares for $945
Reuters  ·  08-20
Protagenic Therapeutics Executive Chair Garo H. Armen Acquires 2,700 Common Shares for $945
Protagenic receives FDA pre-IND feedback supporting IND for PT00114
TIPRANKS  ·  08-20
Protagenic receives FDA pre-IND feedback supporting IND for PT00114
Protagenic Gets FDA Pre-IND Feedback Supporting Planned Phase 1 Trial for Pt00114 in Generalized Anxiety Disorder
Reuters  ·  08-20
Protagenic Gets FDA Pre-IND Feedback Supporting Planned Phase 1 Trial for Pt00114 in Generalized Anxiety Disorder
Protagenic Therapeutics Delays Q2 Form 10-Q Filing, Misses 5-Day Extension Window
Reuters  ·  08-15
Protagenic Therapeutics Delays Q2 Form 10-Q Filing, Misses 5-Day Extension Window
Protagenic Swings to FY26 Net Income of $1.37 Million; Operating Expenses Rise 74% to $4.5 Million
Reuters  ·  08-15
Protagenic Swings to FY26 Net Income of $1.37 Million; Operating Expenses Rise 74% to $4.5 Million
Protagenic Therapeutics Executive Chair Garo H. Armen Buys 2,220 Shares for $710.4
Reuters  ·  08-13
Protagenic Therapeutics Executive Chair Garo H. Armen Buys 2,220 Shares for $710.4
Protagenic Therapeutics Exec Chair Garo H. Armen Acquires 685 Common Shares Worth $150.7
Reuters  ·  08-10
Protagenic Therapeutics Exec Chair Garo H. Armen Acquires 685 Common Shares Worth $150.7
Protagenic Therapeutics Exec Chair Garo H. Armen Acquires 5,000 Common Shares for $1,294
Reuters  ·  08-07
Protagenic Therapeutics Exec Chair Garo H. Armen Acquires 5,000 Common Shares for $1,294
Protagenic Therapeutics Exec Chair Garo H. Armen Acquires 26,291 Common Shares Worth $4,805.99
Reuters  ·  08-04
Protagenic Therapeutics Exec Chair Garo H. Armen Acquires 26,291 Common Shares Worth $4,805.99
Protagenic Therapeutics Delays Annual Report Filing, Seeks Extra Time to Complete Audit
Reuters  ·  06-30
Protagenic Therapeutics Delays Annual Report Filing, Seeks Extra Time to Complete Audit
Protagenic Says Pt00114 Cuts Corticosterone, Anxiety-like Behavior in Chronic Stress Rat Study
Reuters  ·  06-30
Protagenic Says Pt00114 Cuts Corticosterone, Anxiety-like Behavior in Chronic Stress Rat Study
Protagenic announces two engagements to support advancement of PT00114
TIPRANKS  ·  05-19
Protagenic announces two engagements to support advancement of PT00114

Introduction

Company Name.
Protagenic Therapeutics, Inc.
Affiliated Markets:
OTCQB
Listing Date:
--
Main Business:
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Issue price:
--